Skip to main content
Telix Pharmaceuticals Ltd logo

Telix Pharmaceuticals Ltd — Investor Relations & Filings

Ticker · TLX ISIN · AU000000TLX2 ASX Manufacturing
Open in API
Filings indexed 988 across all filing types
Latest filing 2026-04-22 Capital/Financing Update
Country US United States of America
Listing ASX TLX

About Telix Pharmaceuticals Ltd

https://telixpharma.com/

Telix Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals, an approach known as 'theranostics'. The company utilizes targeted radiation to both image and treat various forms of cancer. Its extensive clinical pipeline and portfolio address key areas in oncology, including urologic (prostate and kidney), neurologic (glioma), and musculoskeletal cancers, as well as applications in bone marrow conditioning. Telix has secured global regulatory approvals for its prostate cancer imaging agent and supports its products with a robust global supply, manufacturing, and distribution network. The company is actively engaged in numerous clinical trials worldwide to expand its theranostic platform.

Recent filings

Filing Released Lang Actions
Telix Announces Settlement of US$600M Convertible Bonds 3 pages 220.4KB
Capital/Financing Update Classification · 91% confidence The document is an ASX announcement detailing the successful settlement of $600 million 1.50% convertible notes due 2031, listing of the new bonds, and repurchase and cancellation of existing bonds. It is focused on financing activities and capital structure changes rather than filing a formal report or results. Therefore, it best fits the Capital/Financing Update category.
2026-04-22 English
Notification regarding unquoted securities - TLX 8 pages 23.9KB
Share Issue/Capital Change Classification · 92% confidence The document is an ASX Appendix 3G notice detailing the issue of unquoted convertible debt securities (new class convertible notes) by Telix Pharmaceuticals Limited. It is a formal announcement of a share/capital change (issuance of securities) rather than an earnings release or general report. Therefore it fits the Share Issue/Capital Change category.
2026-04-22 English
Telix Notice of AGM, Proxy Form and Online Guide 44 pages 1.5MB
Proxy Solicitation & Information Statement Classification · 88% confidence The document is an ASX Announcement titled “Notice of Annual General Meeting,” containing the full Notice of Meeting, agenda items, explanatory notes, proxy form instructions, and details on how to vote. It is sent to shareholders to provide information and solicit their votes for the AGM. This fits the definition of a Proxy Solicitation & Information Statement (PSI), rather than simply a report publication announcement or actual AGM presentation.
2026-04-20 English
Convertible Bond Cleansing Notice 144 pages 1.8MB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement outlining the successful pricing and terms of a US$600 million convertible notes issuance by Telix’s subsidiary, including a cleansing notice under section 708A of the Corporations Act. This is a financing activity (debt issuance convertible into equity) and an update on the company’s capital structure. Therefore, it falls under Capital/Financing Update (CAP).
2026-04-19 English
Change in substantial holding 52 pages 2.4MB
Major Shareholding Notification Classification · 95% confidence The document is an Australian Form 604 “Notice of change of interests of substantial holder” under the Corporations Act 2001. It details changes in voting power, relevant interests, and shareholding thresholds for a substantial holder. This corresponds to the “Major Shareholding Notification” category (MRQ) which covers notifications of changes in significant share ownership levels.
2026-04-16 English
Notification of cessation of securities - TLX 5 pages 16.7KB
Share Issue/Capital Change Classification · 70% confidence The document is an ASX Appendix 3H notification detailing the cessation (lapse) of share appreciation and performance rights under the company’s equity incentive plan, including updated issued capital tables. It is a regulatory announcement of changes in the composition of the company’s securities/capital (rights lapsed), which aligns with the “Share Issue/Capital Change” category. There is no discussion of fundraising or debt financing, insider trades, dividends, or voting. Therefore, it is classified as a capital change announcement (SHA).
2026-04-15 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.